12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Go-203-2c: Phase I started

Genus began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-daily IV Go-203-2c for 3 weeks in...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >